



BIONETICS

Litton

Mutagenicity Evaluation of Compound FDA 75-97 (Calcium Carbonate) Final report
9/77

MUTAGENICITY EVALUATION

OF

FDA 75-97
CALCIUM CARBONATE

FINAL REPORT

5516 Nicholson Lane
Kensington, Maryland
20795

MUTAGENICITY EVALUATION

OF

FDA 75-97
CALCIUM CARBONATE

FINAL REPORT

SUBMITTED TO

GENETIC TOXICOLOGY BRANCH
DIVISION OF TOXICOLOGY
BUREAU OF FOODS
U.S. FOOD AND DRUG ADMINISTRATION
200 C STREET, S.W., ROOM 1066
WASHINGTON, D.C.

SUBMITTED BY

LITTON BIONETICS, INC.
5516 NICHOLSON LANE
KENSINGTON, MARYLAND 20795

LBI PROJECT NO. 2672

SEPTEMBER 1977



BIONETICS

Litton

TABLE OF CONTENTS

	Page No.
EVALUATION SUMMARY.....	1
I. <u>OBJECTIVE</u>	2
II. <u>MATERIALS</u>	2
A. Test Compound.....	2
B. Indicator Microorganisms.....	2
C. Reaction Mixture.....	2
D. Tissue Homogenates and Supernatants.....	3
E. Positive Control Compounds.....	3
III. <u>METHODS</u>	3
A. Toxicity.....	3
B. Plate Tests.....	4
C. Suspension Tests.....	4
D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions.....	5
E. Data Recording and Reporting.....	5
IV. <u>RESULTS SECTION</u>	
A. Solubility Properties of the Test Compound.....	6
B. Toxicity and Dosage Determinations for the Test Compound.....	6
C. Plate Assay Results.....	7
D. Suspension Assay Results.....	7
V. <u>INTERPRETATION OF RESULTS AND CONCLUSIONS</u>	15
VI. <u>EXPLANATION OF EVALUATION PROCEDURES FOR PLATE ASSAYS</u>	16
VII. <u>EXPLANATION OF EVALUATION PROCEDURES FOR SUSPENSION ASSAYS</u>	18
APPENDIX - Tabulation of Data.....	A-1

EVALUATION SUMMARY

The test compound, FDA 75-97, Calcium Carbonate, did not exhibit mutagenic activity in any of the assays employed in these studies.

DATE: July, 1977

SPONSOR: U.S. Food and Drug Administration

SUBJECT: Evaluation of Test Compound: FDA 75-97, Calcium Carbonate

I. OBJECTIVE

The objective of this study was to evaluate the test compound for genetic activity in microbial assays with and without the addition of mammalian metabolic activation preparations.

II. MATERIALS

A. Test Compound

1. Date Received: December 29, 1976
2. Description: White powder

B. Indicator Microorganisms

The following strains of indicator microorganisms were used in the evaluation:

Yeast Strain: Saccharomyces cerevisiae, strain D4

Bacteria Strains: Salmonella typhimurium, strains TA-1535
TA-1537
TA-1538
TA-98
TA-100

C. Reaction Mixture

The following reaction mixture was employed in the activation tests:

<u>Component</u>	<u>Final Concentration/ml</u>
1. TPN (sodium salt)	4 μ moles
2. Glucose-6-phosphate	5 μ moles
3. Sodium phosphate (dibasic)	100 μ moles
4. $MgCl_2$	8 μ moles
5. KCl	33 μ moles
6. Homogenate fraction equivalent to 25 mg of wet tissue.	

D. Tissue Homogenates and Supernatants

The tissue homogenates and 9,000 x g supernatants were prepared from tissues of the following mammalian species: Mouse - ICR random bred adult males; rat - Sprague-Dawley adult males; and monkey - Macaca mulatta adult males.

E. Positive Control Compounds

Table 1 lists chemicals for positive controls in the direct and activation assays.

TABLE 1
POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

<u>Assay</u>	<u>Chemical</u> ^a	<u>Solvent</u>	<u>Probable Mutagenic Specificity</u>
Nonactivation	Methylnitrosoguanidine	Water or saline	BPS ^b
	Ethylmethanesulfonate	Water or saline	BPS ^b
	2-Nitrofluorene	Dimethylsulfoxide ^c	FS ^b
	Quinacrine mustard	Water or saline	FS ^b
Activation	Dimethylnitrosamine	Water or saline	BPS ^b
	2-Acetylaminofluorene	Dimethylsulfoxide ^c	FS ^b
	8-Aminoquinoline	Dimethylsulfoxide ^c	FS ^b
	2-Aminoanthracene	Dimethylsulfoxide ^c	BPS ^b

^a Concentrations given in the Results Section

^b BPS = base-pair substitution; FS = frameshift

^c Previously shown to be non-mutagenic

III. METHODS

A. Toxicity

The solubility, toxicity and doses for the test chemical were determined prior to screening.

The test chemical was tested for toxicity against specific indicator strains over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival concentrations and the 1/4 and 1/2 50% doses calculated.

If no toxicity was obtained for the chemical with a given strain, then a maximum dose of 5% (w/v) was used.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.

B. Plate Tests (Overlay Method)

Approximately 10^8 cells from an overnight culture of each indicator strain were added to test tubes containing 2.0 ml of molten agar supplemented with biotin and a trace of histidine. For nonactivation tests, the three dose levels of the test compound were added to the contents of the appropriate tubes and poured over the surfaces of selective agar plates. In activation tests 0.5 ml of a 9,000 x g tissue supernatant and required cofactors (core reaction mixture) were added to the overlay tubes. Three dose levels of the test chemical were added to the appropriate tubes, which were then mixed and the contents poured over the surface of a minimal agar (selective medium) plate and allowed to solidify. The plates were incubated for 48 to 72 hours at 37°C, and scored for the number of colonies growing on each plate. The concentrations of all chemicals are given in the Results Section. Positive and solvent controls using positive compounds that are active directly and those that require metabolic activation were run with each assay.

C. Suspension Tests

1. Nonactivation

Bacteria and yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of 1×10^{10} cells/ml and 5×10^9 cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in plastic, 24-well tissue culture plates (Linbro). Cells plus appropriate volume(s) of the test chemical were added to the wells to give a final volume of 1.5 ml. The solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the plates were set on ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium in reversion experiments. Samples from a 10^{-1} dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C. The yeast plates were incubated at 30°C for 3-5 days before scoring.

2. Activation

Bacteria and yeast cells were grown and prepared as described in the nonactivation tests. Measured amounts of the test and control chemicals plus 0.25 ml of the stock-cell suspension were added to wells of the Linbro plate containing the appropriate tissue fraction and reaction mixture. All flasks (bacteria and yeast) were incubated at 37°C with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for nonactivation tests.

D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

Male animals (except monkeys) sufficient to provide the necessary quantities of tissues were killed by cranial blow, decapitated and bled. Monkey tissues were obtained from freshly killed and bled male rhesus monkeys. Organs were immediately dissected from the animals using aseptic techniques and placed in ice-cold 0.15M KCl. Upon collection of the desired quantity of organs, they were washed twice with fresh KCl and completely homogenized with a motor-driven homogenizing unit at 4°C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at -80°C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at -80°C. These two frozen samples were used for the activation studies. Protein and P-448 determinations were made for each lot of homogenate.

E. Data Recording and Reporting

1. Plate test assays

The numbers of colonies on each plate were counted and recorded on printed forms. These raw data were entered into a computer program designed to print out all data by test. The data are presented as revertants per plate for each indicator strain employed in the assay. The positive and solvent controls are provided as reference points.

2. Suspension assays

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, on data processing forms. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. Other relevant experimental data were recorded on experimental definition forms. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated. The data were then processed and printed from a computer program. All raw data sheets are dated and signed by the responsible technician.

IV. RESULTS SECTION

A. Solubility Properties of the Test Compound

1. Name or code designation of the test compound: FDA 75-97, Calcium Carbonate
2. Test solvent: * Saline
3. Solubility of the test compound under treatment conditions: Soluble
4. Additional comments: White powder

B. Toxicity and Dosage Determinations for the Test Compound

1. Test date for toxicity determination: April 4, 1977
2. The 50% survival level was determined for bacteria and yeast indicator organisms by conducting survival curves with the test compound at the following concentrations:

Percent Concentration (w/v or v/v)

5.0
0.5
0.05
0.005
0.0005

3. Concentrations of the test compound used in the mutagenicity tests:

<u>Test Doses</u>	<u>Percent Concentration</u>	
	<u>Bacteria</u>	<u>Yeast</u>
1/4 50% Survival	01.25	01.25
1/2 50% Survival	02.50	02.50
50% Survival	05.00	05.00

*The concentration of solvent was equal to the highest volume of test material added.

C. Plate Test Results

The plate test results are summarized in the following table. The values presented in this table are the number of revertants per plate.

D. Suspension Assay Results

The suspension test results for the test compound are summarized in the tables following the plate test summary. The values presented in these tables are the calculated mutation frequencies for each control and experimental test point. The first table of the suspension set presents the results for the nonactivation assays, and the second table through the fourth table of the suspension set presents the results for the activation assays. A listing of computer codes and abbreviations is included for reference. Tabulation of all raw data is provided in the Appendix.

SUMMARY OF TEST RESULTS

PLATE TESTS

A. NAME OR CODE DESIGNATION OF THE TEST COMPOUND: 000471341
 B. TEST DATE: MAY 18, 1977

TEST	SPECIES	ISSUE	REVERTANTS PER PLATE									
			TA-1535		TA-1537		TA-1538		TA-98		TA-100	
			1	2	1	2	1	2	1	2	1	2
1. NON-ACTIVATION												
SOLVENT CONTROL*	---	---	28	21	22	35	17	16	34	27	148	143
POSITIVE CONTROL**	---	---	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000
TEST 5.00000 %	---	---	29	16	19	19	10	21	29	30	153	160
2.50000 %	---	---	22	15	16	10	11	12	32	21	156	135
1.25000 %	---	---	30	21	16	14	13	17	27	22	133	137
2. ACTIVATION												
SOLVENT CONTROL*	MOUSE	LIVER	30	31	22	23	19	10	37	32	222	195
	RAT	LIVER	26	37	20	18	19	17	39	40	147	182
	MONKEY	LIVER	18	15	17	31	23	21	36	37	192	133
POSITIVE CONTROL***	MOUSE	LIVER	502	490	260	256	874	911	>1000	>1000	624	889
	RAT	LIVER	274	374	241	149	938	732	>1000	>1000	>1000	>1000
	MONKEY	LIVER	370	215	173	160	738	901	>1000	937	>1000	>1000
TEST 5.00000 %	MOUSE	LIVER	15	13	14	22	22	19	43	41	97	155
2.50000 %	MOUSE	LIVER	13	19	29	26	16	17	36	48	164	101
1.25000 %	MOUSE	LIVER	16	20	19	14	24	22	29	38	118	199
5.00000 %	RAT	LIVER	15	26	17	16	18	25	35	38	158	179
2.50000 %	RAT	LIVER	17	15	14	17	20	21	45	41	141	125
1.25000 %	RAT	LIVER	21	16	16	10	12	16	39	33	128	139
5.00000 %	MONKEY	LIVER	18	20	19	14	19	18	39	37	123	104
2.50000 %	MONKEY	LIVER	19	17	18	19	13	14	36	32	133	139
1.25000 %	MONKEY	LIVER	19	18	19	13	17	19	37	34	122	147

* NON-ACTIVATION ASSAYS CONSIST OF THE CELLS PLUS THE TEST COMPOUND VEHICLE (SOLVENT). FOR ACTIVATION ASSAYS, THE OVERLAY CONTAINS THE ACTIVATION SYSTEM PLUS THE TEST COMPOUND VEHICLE.

** TA-1535 MNNG 2 UG/PLATE
 TA-1537 QM 20 UG/PLATE
 TA-1538 NF 100 UG/PLATE
 TA-98 NF 100 UG/PLATE
 TA-100 MNNG 2 UG/PLATE

*** TA-1535 ANTH 100 UG/PLATE
 TA-1537 AMQ 100 UG/PLATE
 TA-1538 AAF 100 UG/PLATE
 TA-98 AAF 100 UG/PLATE
 TA-100 ANTH 100 UG/PLATE

NOTE: CONCENTRATIONS ARE GIVEN IN MICROLITERS(UL) OR MICROGRAMS(UG) PER PLATE.

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/22/77

NONACTIVATION COMPOUND 000471341

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
NAN		85.71	3.58	11.59	5.46	13.83	19.91	6.89
NAP		900.49	685.45	235.32	163.30	71.70	109.36	78.06
<hr/>								
NA1		61.18	3.44	2.62	4.65	7.55	19.96	10.16
NA2		64.66	3.10	2.83	4.26	6.93	27.90	5.91
NA3		60.51	3.11	3.52	4.27	7.16	28.78	5.39

CONTROLS

TEST DATA

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/22/77

SPECIES ICRFLO/MOUSE COMPOUND 000471341

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5	
ACT	A+C	84.43	3.81	9.31	15.20	9.46	6.93	15.63	NEGATIVE CONTROLS
ACT	A-C	55.84	5.81	6.29	5.26	8.79	6.90	22.67	
ACT	ALI	57.41	5.02	12.74	5.19	21.48	10.38	8.14	
ACT	ALU	58.69	5.12	7.03	11.70	14.70	5.15	15.00	

ACT	PLI	182.07	162.45	97.65	294.83	87.28	53.36	91.82	POSITIVE CONTROLS
ACT	PLU	91.94	7.85	4.19	34.19	74.60	19.04	17.34	

ACT	LI1	40.27	5.73	23.91	3.76	15.79	14.88	6.85	TEST COMPOUND
ACT	LI2	21.46	6.40	15.57	2.90	10.78	8.31	6.79	
ACT	LI3	27.97	5.41	15.78	3.15	12.72	12.89	7.13	
ACT	LU1	29.19	6.53	12.34	5.38	10.13	14.64	6.61	
ACT	LU2	26.50	8.51	17.14	14.63	14.65	14.63	7.02	
ACT	LU3	35.26	7.67	17.13	8.99	14.11	12.29	5.62	

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/22/77

SPECIES SPRDAW/RAT COMPOUND 000471341

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5	
ACT	A+C	20.79	1.37	2.13	10.56	13.11	15.60	10.18	NEGATIVE CONTROLS
ACT	A-C	18.64	3.80	6.21	5.06	15.56	12.85	7.44	
ACT	ALI	83.48	2.64	7.26	10.82	36.48	15.01	10.34	
ACT	ALU	64.68	1.76	2.62	10.33	17.83	15.67	10.27	
ACT	PLI	247.96	411.39	116.25	88.95	297.10	110.32	71.61	POSITIVE CONTROLS
ACT	PLU	52.63	1.29	3.16	160.05	124.87	17.35	7.69	
ACT	L11	45.45	1.51	8.99	1.95	35.94	11.74	13.42	TEST COMPOUND
ACT	L12	37.60	2.71	6.13	5.19	45.39	11.93	13.39	
ACT	L13	55.34	2.13	6.13	5.86	38.43	9.38	8.31	
ACT	LU1	51.79	1.25	5.93	4.27	17.74	11.58	12.56	
ACT	LU2	46.79	3.55	5.45	11.29	19.36	13.43	15.09	
ACT	LU3	35.60	2.93	3.81	9.42	14.52	21.20	7.17	

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/22/77

SPECIES RHESUS/MONKEY COMPOUND 000471341

TEST	ORG	TA100 HIS EX-R	TA1535 HIS EX-R	TA1537 HIS EX-R	TA1538 HIS EX-R	TA98 HIS EX-R	0000D4 ADE EX-5	0000D4 TRY EX-5	
ACT	A+C	87.84	5.64	21.88	13.86	7.51	21.98	10.90	NEGATIVE CONTROLS
ACT	A-C	64.54	2.96	1.25	11.47	8.19	8.04	7.30	
ACT	ALI	80.09	5.54	4.98	12.37	14.55	16.25	6.21	
ACT	ALU	70.23	3.78	7.32	10.10	10.45	20.74	7.73	
<hr/>									
ACT	PLI	284.60	56.90	37.74	154.01	201.65	68.25	54.23	POSITIVE CONTROLS
ACT	PLU	69.20	4.38	13.64	7.74	8.22	20.46	7.34	
<hr/>									
ACT	L11	86.07	3.79	6.63	4.11	8.30	20.90	12.21	TEST COMPOUND
ACT	L12	51.79	3.42	5.38	4.04	9.32	14.93	11.37	
ACT	L13	77.70	4.95	4.42	5.69	9.43	23.08	12.66	
ACT	LU1	89.28	7.06	3.60	2.30	11.85	14.59	9.19	
ACT	LU2	80.64	4.39	2.57	2.52	10.57	20.87	11.17	
ACT	LU3	78.12	8.93	2.98	4.16	11.49	17.07	6.50	

DATA TABLE TERMS AND ABBREVIATIONS

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
COMPOUND	Client designated compound number appears in this column.
TEST CODES	<p>NAN = Nonactivation: Solvent Control NAP = Nonactivation: Positive Control NA1 = Nonactivation: Test Compound Dose 1 NA2, etc. = Reflects the other dose level(s)</p> <p>A+C = Negative Chemical Control for ACP A-C = Activation: Solvent Control ALI or A+T = Activation: Homogenate Control (Liver) ALU = Activation: Homogenate Control (Lung) ACP = Activation: Positive Control ACT = Activation Test</p> <p>LI = Liver Tissue Activation Fraction LU = Lung Tissue Activation Fraction KI = Kidney Tissue Activation Fraction TE = Testes Tissue Activation Fraction 1,2, etc. = Dose Levels</p>
CONCENTRATION	<p>All test compound dose levels are expressed as a whole number followed by an exponent (negative) identified by the appropriate units.</p> <p>Example: 0025-2PCT = 0.25 percent concentration</p>
POPU	Total number of viable cells in the plating sample raised to some exponent printed directly below the abbreviation (i.e., EP + 6 = $\times 10^6$).
MUT 1	Total number of mutants or convertants obtained from the sample plated raised to some exponent printed directly below the abbreviation (i.e., EP + 0 = 10^0). For strain D4, MUT 1 represents the number of ADE+ convertants.
MUT 2	Only used for strain D4 and represents the number of TRY+ convertants in the plated sample.
FREQ 1	The calculated mutation or gene conversion frequency times the negative exponent written directly below. For strain D4, FREQ 1 represents the ADE+ value.
FREQ 2	Only used for strain D4 and represents the TRY+ conversion frequency.
CONTAM	Presence of contamination on any plates.

DATA TABLE TERMS AND ABBREVIATIONS (continued)

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
AAF	2-Acetylaminofluorene
DMSO	Dimethylsulfoxide
DMN	Dimethylnitrosamine
EMS	Ethylmethanesulfonate
QM	Quinacrine Mustard
NF	Nitrofluorene
ANTH	2-Amino Anthracene
AMQ	8-Amino Quinoline
SPECIES	Animal Strains
SPRDAW	Sprague Dawley Rats
ICRFLO	Flow ICR Random Bred Mice
RHESUS	Rhesus Monkey (<u>Macaca mulatta</u>)
MIXEDB	Dog, Mixed Breed
NEWZEA	New Zealand White Rabbit
UG	Microgram
UM	Micromole
ADE	Adenine
TRY	Tryptophan

V. INTERPRETATION OF RESULTS AND CONCLUSIONS

The test compound, FDA 75-97, Calcium Carbonate, was evaluated for genetic activity in a series of in vitro microbial assays with and without metabolic activation. The following results were obtained:

A. Salmonella typhimurium

1. Plate tests

The results of these tests were negative.

2. Nonactivation suspension tests

The results of these tests were negative.

3. Activation suspension tests

The results of these tests were negative.

B. Saccharomyces cerevisiae

1. Nonactivation suspension tests

The results of these tests were negative.

2. Activation suspension tests

The results of these tests were negative.


C. Conclusions

The test compound, FDA 75-97, Calcium Carbonate, did not exhibit mutagenic activity in any of the assays employed in these studies.

Submitted by:


David J. Brusick, Ph.D. 8/3/77
Director Date
Department of Molecular
Toxicology

Reviewed by:


Robert J. Weir, Ph.D. 8/3/77
Vice President Date

VI. EXPLANATION OF EVALUATION PROCEDURES FOR PLATE ASSAYS

Plate test data consist of direct revertant colony counts obtained from a set of selective agar plates seeded with populations of mutant cells suspended in a semisolid overlay. Because the test chemical and cells are incubated in the overlay for 2-3 days, and a few cell divisions occur during the incubation period, the test is semiquantitative in nature. Although these features of the assay reduce the quantitation of results, they provide certain advantages not contained in a quantitative suspension test.

- The small number of cell divisions permits potential mutagens to act on replicating DNA which is often more sensitive than non-replicating DNA.
- The combined incubation of the compound and the cells in the overlay permit constant exposure of the indicator cells for 2-3 days.

A. Surviving Populations

Plate test procedures do not permit exact quantitation of the number of cells surviving chemical treatment. At low concentrations of the test chemical, the surviving population on the treatment plates is essentially the same as the negative control plate. At high concentrations, the surviving population is usually reduced by some fraction. Our protocol normally employs dose levels that are selected such that the highest dose will show slight toxicity (as determined by subjective criteria) and several doses ranging down 1 to 2 logs lower.

B. Dose Response Phenomena

The demonstration of dose-related increases in mutant counts is an important criterion in establishing mutagenicity. Factors which may modify dose response results for a mutagen would be the selection of doses that are too low (usually mutagenicity and toxicity are related). If the highest dose is far lower than a toxic concentration, no increases may be observed over the dose range selected. Conversely, if the lowest dose employed is highly cytotoxic, the test chemical may kill any mutants that are induced and the compound will not appear to be mutagenic.

C. Control Tests

Positive and negative control assays are conducted with each experiment and consist of direct acting mutagens for nonactivation assays and mutagens that require metabolic biotransformation in activation assays. Negative controls consist of the test compound solvent in the overlay agar with the other essential components. The negative control plate for each strain gives a reference point to which the test data are compared. The positive control assay is conducted to demonstrate that the test systems are functional with known mutagens.

D. Evaluation Criteria for Ames Assay

Because the procedures used to evaluate the mutagenicity of the test chemical are semiquantitative, the criteria used to determine positive effects are inherently subjective and are based primarily on a historical data base. Most data sets are evaluated using the following criteria:

1. Strains TA-1535, TA-1537, and TA-1538

If the solvent control value is within the normal range, a chemical that produces a positive dose response over three concentrations with the lowest increase equal to twice the solvent control value is considered to be mutagenic.

2. Strains TA-98, TA-100, and D4

If the solvent control value is within the normal range, a chemical that produces a positive dose response over three concentrations with the highest increase equal to twice the solvent control value for TA-100 and two to three times the solvent control value for strains TA-98 and D4 is considered to be mutagenic. For these strains, the dose response increase should start at approximately the solvent control value.

3. Pattern

Because TA-1535 and TA-100 were both derived from the same parental strain (G-46) and because TA-1538 and TA-98 were both derived from the same parental strain (D3052), there is a built-in redundancy in the microbial assay. In general the two strains of a set respond to the same mutagen and such a pattern is sought. It is also anticipated that if a given strain, e.g. TA-1537, responds to a mutagen in nonactivation tests it will generally do so in activation tests. (The converse of this relationship is not expected.) While similar response patterns are not required for all mutagens, they can be used to enhance the reliability of an evaluation decision.

4. Reproducibility

If a chemical produces a response in a single test that cannot be reproduced in one or more additional runs, the initial positive test data loses significance.

The preceding criteria are not absolute and other extenuating factors may enter into a final evaluation decision. However, these criteria are applied to the majority of situations and are presented to aid those individuals not familiar with this procedure. As the data base is increased, the criteria for evaluation can be more firmly established.

VII. EXPLANATION OF EVALUATION PROCEDURES FOR SUSPENSION ASSAYS

Data obtained from mutagenicity tests are evaluated on a test by test basis followed by an examination of the total response pattern using all the data. To facilitate this type of evaluation, we have prepared two separate formats in which data are processed. The first is the Compound Summary Backup Detail Sheet, which details the essential raw data from each experiment showing surviving population counts, total mutant or revertant counts, as well as, calculated mutation frequencies. This format permits close examination of each set of test data. The following considerations are part of any assessment.

A. Surviving Population Counts

A certain level of chemically-induced toxicity is anticipated, but occasionally isolated tests or groups of tests show very low (<25%) survival compared to the tissue controls. Such isolated decreases may result from improper dilution procedures or defective growth media and decrease confidence in the calculated mutation frequencies especially if the total mutant counts appear unaffected. Data of this type are generally unacceptable and these experiments are routinely repeated at a lower dose level to reduce killing and increase confidence in the nature of the response.

B. Total Mutant Counts

For nonmutagens, the mutant/surviving population ratio should be roughly equivalent for each test point in a given experiment. If the cell number drops in response to killing, the mutant number should decrease proportionately. A mutagenic chemical, however, will produce an altered mutant/surviving population ratio. Mutant numbers as well as calculated frequencies are compared to the negative control data. In certain instances, the mutant frequencies will increase with little or no change in the absolute number of mutants especially where the test chemical is toxic. Data of this type, although not necessarily aberrant, or even rare, must be viewed with special care to ensure that the increased frequencies were not the result of selective toxicity of the test chemical for the his cells. This phenomenon, referred to as selection, can lead to erroneous conclusions. Thus we attempt to keep the surviving population of cells high and look for positive responses that show increases in both numbers of mutants and mutation frequencies. Again, occasional isolated fluctuations in mutant counts are found that can be attributed to improper pipetting or media contamination. These fluctuations are usually easy to identify by inspection of the other data points in the experiment which will be negative.

C. Dose Response Phenomena

Dose-related increases in mutants and mutation frequencies are the most convincing data to have in assessing mutagenic activity of chemicals. In some cases, however, dose-related increases are not observed for mutagens. This depends considerably on the dose levels selected. The figure on the following page illustrates how one might obtain various types of dose-related responses by a mutagen based solely on dose selection. It also emphasizes the need to keep dose levels within a relatively low range of toxicity so that data are consistently on the uphill side of the hypothetical curve.


D. Control Tests

Positive and negative control tests are conducted with each experiment and consist of direct acting positive agents for nonactivation assays and chemicals that require metabolic transformation for activation assays. In nonactivation assays, the NAN control contain the test chemical solvent plus cells, but no chemical, and is used as a reference to assess the level of response obtained in the various tests. It is not possible at this time to put precise cut-off points where negative responses become positive responses. A statistical component for our computer program is under development and will be included when available. Positive controls are only used as relative reference points and to demonstrate that the system is functioning with known mutagens. In activation assays, three types of negative controls are run: (1) A solvent control minus the chemical and minus the activation system (A-C); (2) a control plus the positive control chemical minus the activation system (A+C); and (3) a control containing the activation system and the test chemical solvent (ALI or ALU). All three controls are used collectively to assess the level of response in the various activation tests. A chemical may appear positive when compared to an A-C control but not when compared to an A+T control. The value of each of the above controls with respect to their weight in evaluation is $ALI \text{ or } ALU > A-C > A+C$.

The other data format is the Compound Frequency Summary Report sheet in which all the calculated frequencies obtained for a given compound are displayed in a table. This format permits an overview of all data. The points form a matrix of information that should present a consistent pattern. Nonmutagens should produce a matrix with data frequencies clustered around the negative control values. Occasional random high or low fluctuations are not uncommon and seldom indicate true genetic activity. Mutagenic chemicals should, on the other hand, produce a set of consistent responses that demonstrate a logical pattern. The patterns depend on the mutagenic specificity of the chemical but can be easily recognized in the Compound Frequency Summary Report format.

These mutagenicity assays are designed to optimize the probability of recognizing mutagens from nonmutagens and, in most cases, they work well. Occasionally, the data points are such that a definitive conclusion cannot be made without additional data.

HYPOTHETICAL MUTATION AND TOXICITY KINETICS



HYPOTHETICAL EXPERIMENT

- (1) Dose levels 1, 2 & 3 were used
- (2) Dose levels 2, 3 & 4 were used
- (3) Dose levels 3, 4 & 5 were used

OBSERVED DOSE RESPONSE

A typical positive dose response set of data would be obtained.

The intermediate dose level shows a higher mutation frequency than both the low dose and the high dose.

Here an inverted dose response would be observed with the highest dose level showing the lowest response.

APPENDIX
Tabulation of Data



BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 223-76-2102			PROJECT 2672		
EXPERIMENT 710203		DETECTOR TA100	SPECIES		/	DATE - 07/22/77	
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
		NAN	SOLVENT	0252	0216	85.71	0
		NAP	EMS 0.066%	0616	5547	900.49	0
000471341	NA1		0005-0 PCT.	0953	0583	61.18	0
000471341	NA2		0025-1 PCT.	0945	0611	64.66	0
000471341	NA3		0125-2 PCT.	0790	0478	60.51	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102		PROJECT 2672		DATE - 07/22/77			
EXPERIMENT 710201		DETECTOR TA1535		SPECIES /			
COMPOUND	TEST ID	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0810	0029	3.58	0
	NAP		EMS 0.2%	0852	5840	685.45	0
000471341	NA1		0005-0 PCT.	0929	0032	3.44	0
000471341	NA2		0025-1 PCT.	1260	0039	3.10	0
000471341	NA3		0125-2 PCT.	1093	0034	3.11	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 223-76-2102		PROJECT 2672		DATE - 07/22/77	
EXPERIMENT 710101		DETECTOR TA1537		SPECIES /			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
		NAN	SOLVENT	0466	0054	11.59	0
		NAP	QM 13 UG/ML	0235	0553	235.32	0
000471341	NA1		0005-0 PCT.	1030	0027	2.62	0
000471341	NA2		0025-1 PCT.	1343	0038	2.83	0
000471341	NA3		0125-2 PCT.	1477	0052	3.52	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 223-76-2102		PROJECT 2672		DATE - 07/22/77	
EXPERIMENT 705306		DETECTOR TA1538		SPECIES /			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
		NAN	SOLVENT	0403	0022	5.46	0
		NAP	NF 667 UG/ML	0376	0614	163.30	0
000471341	NA1		0005-0 PCT.	0516	0024	4.65	0
000471341	NA2		0025-1 PCT.	0446	0019	4.26	0
000471341	NA3		0125-2 PCT.	0539	0023	4.27	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102		PROJECT 2672		DATE - 07/22/77			
EXPERIMENT 710202	DETECTOR TA98	SPECIES /					
COMPOUND	TEST ID	ORG	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0962	0133	13.83	0
	NAP		NF 667 UG/ML	0834	0598	71.70	0
000471341	NA1		0005-0 PCT.	1523	0115	7.55	0
000471341	NA2		0025-1 PCT.	1429	0099	6.93	0
000471341	NA3		0125-2 PCT.	1621	0116	7.16	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102		PROJECT 2672		DATE - 07/22/77					
EXPERIMENT 710902	DETECTOR 000004	SPECIES /							
COMPOUND	TEST ID	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	NAN		SOLVENT	1175	0234	0081	19.91	6.89	1
	NAP		EMS 1.0 %	1463	1600	1142	109.36	78.06	0
000471341	NA1		0005-0 PCT.	0571	0114	0058	19.96	10.16	1
000471341	NA2		0025-1 PCT.	2115	0590	0125	27.90	5.91	0
000471341	NA3		0125-2 PCT.	2172	0625	0117	28.78	5.39	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 710301 DETECTOR TA100 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0989	0835	84.43	0
	A-C		SOLVENT	0899	0502	55.84	0
	ALI		TISSUE	1545	0887	57.41	0
	ALU		TISSUE	1869	1097	58.69	0
	ACP	LT	DMN 90 UM/ML	1160	2112	182.07	0
	ACP	LU	DMN 90 UM/ML	0496	0456	91.94	0
000471341	ACT	LI1	0005-0 PCT.	1619	0652	40.27	0
000471341	ACT	LI2	0025-1 PCT.	2567	0551	21.46	0
000471341	ACT	LI3	0125-2 PCT.	1580	0442	27.97	0
000471341	ACT	LU1	0005-0 PCT.	1463	0427	29.19	0
000471341	ACT	LU2	0025-1 PCT.	1419	0376	26.50	0
000471341	ACT	LU3	0125-2 PCT.	1605	0566	35.26	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 704041 DETECTOR TA1535 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0656	0025	3.81	0
	A-C		SOLVENT	0430	0025	5.81	0
	ALI		TISSUE	0617	0031	5.02	0
	ALU		TISSUE	0645	0033	5.12	0
	ACP	LI	DMN 90 UM/ML	0490	0796	162.45	0
	ACP	LU	DMN 90 UM/ML	0586	0046	7.85	0
000471341	ACT	L11	0005-0 PCT.	0611	0035	5.73	0
000471341	ACT	L12	0025-1 PCT.	0500	0032	6.40	0
000471341	ACT	L13	0125-2 PCT.	0536	0029	5.41	0
000471341	ACT	LU1	0005-0 PCT.	0582	0038	6.53	0
000471341	ACT	LU2	0025-1 PCT.	0611	0052	8.51	0
000471341	ACT	LU3	0125-2 PCT.	0652	0050	7.67	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 710802 DETECTOR TA1537 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	2235	0208	9.31	0
	A-C		SOLVENT	2639	0166	6.29	0
	ALI		TISSUE	0769	0098	12.74	0
	ALU		TISSUE	0768	0054	7.03	0
	ACP	LI	AMQ 333 UG/ML	2337	2282	97.65	0
	ACP	LU	AMQ 333 UG/ML	0382	0016	4.19	2
000471341	ACT	LI1	0005-0 PCT.	1096	0262	23.91	0
000471341	ACT	LI2	0025-1 PCT.	1233	0192	15.57	0
000471341	ACT	LI3	0125-2 PCT.	1217	0192	15.78	0
000471341	ACT	LU1	0005-0 PCT.	1240	0153	12.34	0
000471341	ACT	LU2	0025-1 PCT.	0846	0145	17.14	0
000471341	ACT	LU3	0125-2 PCT.	0829	0142	17.13	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 711804 DETECTOR TA1538 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0171	0026	15.20	0
	A-C		SOLVENT	0323	0017	5.26	0
	ALI		TISSUE	0385	0020	5.19	0
	ALU		TISSUE	0265	0031	11.70	0
	ACP	LI	ANTH 67 UG/ML	0329	0970	294.83	0
	ACP	LU	ANTH 67 UG/ML	0310	0106	34.19	0
000471341	ACT	L11	0005-0 PCT.	0319	0012	3.76	0
000471341	ACT	L12	0025-1 PCT.	0482	0014	2.90	0
000471341	ACT	L13	0125-2 PCT.	0540	0017	3.15	0
000471341	ACT	LU1	0005-0 PCT.	0446	0024	5.38	0
000471341	ACT	LU2	0025-1 PCT.	0123	0018	14.63	0
000471341	ACT	LU3	0125-2 PCT.	0189	0017	8.99	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 710304 DETECTOR TA98 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	1797	0170	9.46	0
	A-C		SOLVENT	1513	0133	8.79	0
	ALI		TISSUE	0810	0174	21.48	0
	ALU		TISSUE	1095	0161	14.70	0
	ACP	LI	ANTH 67 UG/ML	0629	0549	87.28	0
	ACP	LU	ANTH 67 UG/ML	1134	0846	74.60	0
000471341	ACT	LI1	0005-0 PCT.	0975	0154	15.79	0
000471341	ACT	LI2	0025-1 PCT.	1503	0162	10.78	0
000471341	ACT	LI3	0125-2 PCT.	1258	0160	12.72	0
000471341	ACT	LU1	0005-0 PCT.	1481	0150	10.13	0
000471341	ACT	LU2	0025-1 PCT.	1140	0167	14.65	0
000471341	ACT	LU3	0125-2 PCT.	1191	0168	14.11	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 712902 DETECTOR 0000D4 SPECIES ICRFLO/MOUSE DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	1184	0082	0185	6.93	15.63	0
	A-C		SOLVENT	1072	0074	0243	6.90	22.67	0
	ALI		TISSUE	1474	0153	0120	10.38	8.14	0
	ALU		TISSUE	1320	0068	0198	5.15	15.00	0
	ACP	LI	DMN 90 UM/ML	1222	0652	1122	53.36	91.82	0
	ACP	LU	DMN 90 UM/ML	1061	0202	0184	19.04	17.34	0
000471341	ACT	LI1	0005-0 PCT.	1270	0189	0087	14.88	6.85	0
000471341	ACT	LI2	0025-1 PCT.	1782	0148	0121	8.31	6.79	0
000471341	ACT	LI3	0125-2 PCT.	2063	0266	0147	12.89	7.13	0
000471341	ACT	LU1	0005-0 PCT.	1892	0277	0125	14.64	6.61	0
000471341	ACT	LU2	0025-1 PCT.	1852	0271	0130	14.63	7.02	0
000471341	ACT	LU3	0125-2 PCT.	1814	0223	0102	12.29	5.62	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 711003 DETECTOR TA100 SPECIES SPRDAW/RAT DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0404	0084	20.79	0
	A-C		SOLVENT	0499	0093	18.64	0
	ALI		TISSUE	0230	0192	83.48	0
	ALU		TISSUE	0487	0315	64.68	0
	ACP	LI	DMN 90 UM/ML	0319	0791	247.96	0
	ACP	LU	DMN 90 UM/ML	0779	0410	52.63	0
000471341	ACT	LI1	0005-0 PCT.	0572	0260	45.45	0
000471341	ACT	LI2	0025-1 PCT.	0500	0188	37.60	0
000471341	ACT	LI3	0125-2 PCT.	0459	0254	55.34	0
000471341	ACT	LU1	0005-0 PCT.	0614	0318	51.79	0
000471341	ACT	LU2	0025-1 PCT.	0731	0342	46.79	0
000471341	ACT	LU3	0125-2 PCT.	0972	0346	35.60	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 711103 DETECTOR TA1535 SPECIES SPRDAW/RAT DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	1388	0019	1.37	0
	A-C		SOLVENT	0841	0032	3.80	0
	ALI		TISSUE	1442	0038	2.64	0
	ALU		TISSUE	1420	0025	1.76	0
	ACP	LI	DMN 90 UM/ML	1141	4694	411.39	0
	ACP	LU	DMN 90 UM/ML	1393	0018	1.29	0
000471341	ACT	LI1	0005-0 PCT.	1258	0019	1.51	0
000471341	ACT	LI2	0025-1 PCT.	1146	0031	2.71	0
000471341	ACT	LI3	0125-2 PCT.	1219	0026	2.13	0
000471341	ACT	LU1	0005-0 PCT.	0959	0012	1.25	0
000471341	ACT	LU2	0025-1 PCT.	1212	0043	3.55	0
000471341	ACT	LU3	0125-2 PCT.	1297	0038	2.93	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 713053 DETECTOR TA1537 SPECIES SPRDAW/RAT DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	0658	0014	2.13	0
	A-C		SOLVENT	0692	0043	6.21	0
	ALI		TISSUE	0496	0036	7.26	0
	ALU		TISSUE	0687	0018	2.62	0
	ACP	LI	AMQ 333 UG/ML	0437	0508	116.25	0
	ACP	LU	AMQ 333 UG/ML	0696	0022	3.16	0
000471341	ACT	LI1	0005-0 PCT.	0434	0039	8.99	0
000471341	ACT	LI2	0025-1 PCT.	0473	0029	6.13	0
000471341	ACT	LI3	0125-2 PCT.	0506	0031	6.13	0
000471341	ACT	LU1	0005-0 PCT.	0607	0036	5.93	0
000471341	ACT	LU2	0025-1 PCT.	0624	0034	5.45	0
000471341	ACT	LU3	0125-2 PCT.	0682	0026	3.81	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 712501 DETECTOR TA1538 SPECIES SPRDAW/RAT DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0956	0101	10.56	0
	A-C		SOLVENT	1244	0063	5.06	2
	ALI		TISSUE	0536	0058	10.82	0
	ALU		TISSUE	0552	0057	10.33	0
	ACP	LI	ANTH 67 UG/ML	0977	0869	88.95	0
	ACP	LU	ANTH 67 UG/ML	0443	0709	160.05	0
000471341	ACT	LI1	0005-0 PCT.	0871	0017	1.95	0
000471341	ACT	LI2	0025-1 PCT.	0847	0044	5.19	0
000471341	ACT	LI3	0125-2 PCT.	0785	0046	5.86	0
000471341	ACT	LU1	0005-0 PCT.	0632	0027	4.27	0
000471341	ACT	LU2	0025-1 PCT.	0558	0063	11.29	0
000471341	ACT	LU3	0125-2 PCT.	0711	0067	9.42	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102		PROJECT 2672					
EXPERIMENT 715101		DETECTOR TA98		SPECIES SPRDAW/RAT		DATE - 07/22/77	
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0915	0120	13.11	0
	A-C		SOLVENT	0405	0063	15.56	0
	ALI		TISSUE	0455	0166	36.48	0
	ALU		TISSUE	1127	0201	17.83	0
	ACP	LI	ANTH 67 UG/ML	0483	1435	297.10	0
	ACP	LU	ANTH 67 UG/ML	0961	1200	124.87	0
000471341	ACT	L11	0005-0 PCT.	0985	0354	35.94	0
000471341	ACT	L12	0025-1 PCT.	0597	0271	45.39	0
000471341	ACT	L13	0125-2 PCT.	0497	0191	38.43	0
000471341	ACT	LU1	0005-0 PCT.	1144	0203	17.74	0
000471341	ACT	LU2	0025-1 PCT.	1007	0195	19.36	0
000471341	ACT	LU3	0125-2 PCT.	1054	0153	14.52	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 712901 DETECTOR 000004 SPECIES SPRDAW/RAT DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	1051	0164	0107	15.60	10.18	0
	A-C		SOLVENT	1533	0197	0114	12.85	7.44	0
	ALI		TISSUE	1306	0196	0135	15.01	10.34	0
	ALU		TISSUE	1091	0171	0112	15.67	10.27	0
	ACP	LI	DMN 90 UM/ML	1173	1294	0840	110.32	71.61	0
	ACP	LU	DMN 90 UM/ML	1118	0194	0086	17.35	7.69	0
000471341	ACT	LI1	0005-0 PCT.	1133	0133	0152	11.74	13.42	0
000471341	ACT	LI2	0025-1 PCT.	1031	0123	0138	11.93	13.39	0
000471341	ACT	LI3	0125-2 PCT.	1216	0114	0101	9.38	8.31	0
000471341	ACT	LU1	0005-0 PCT.	1338	0155	0168	11.58	12.56	0
000471341	ACT	LU2	0025-1 PCT.	1087	0146	0164	13.43	15.09	0
000471341	ACT	LU3	0125-2 PCT.	0934	0198	0067	21.20	7.17	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 223-76-2102	PROJECT 2672			
EXPERIMENT 710401		DETECTOR TA100	SPECIES RHESUS/MONKEY		DATE - 07/22/77	
COMPOUND	TEST	ORG ID CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C	DMN 90 UM/ML	0839	0737	87.84	0
	A-C	SOLVENT	0863	0557	64.54	0
	ALI	TISSUE	0874	0700	80.09	0
	ALU	TISSUE	0823	0578	70.23	0
	ACP	LI DMN 90 UM/ML	0617	1756	284.60	0
	ACP	LU DMN 90 UM/ML	1013	0701	69.20	0
000471341	ACT	LI1 0005-0 PCT.	0840	0723	86.07	0
000471341	ACT	LI2 0025-1 PCT.	1344	0696	51.79	0
000471341	ACT	LI3 0125-2 PCT.	1000	0777	77.70	0
000471341	ACT	LU1 0005-0 PCT.	0746	0666	89.28	0
000471341	ACT	LU2 0025-1 PCT.	0816	0658	80.64	0
000471341	ACT	LU3 0125-2 PCT.	1042	0814	78.12	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 710402 DETECTOR TA1535 SPECIES RHESUS/MONKEY DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0887	0050	5.64	0
	A-C		SOLVENT	0945	0028	2.96	0
	ALI		TISSUE	0903	0050	5.54	0
	ALU		TISSUE	0846	0032	3.78	0
	ACP	LI	DMN 90 UM/ML	1160	0660	56.90	0
	ACP	LU	DMN 90 UM/ML	1028	0045	4.38	0
000471341	ACT	LI1	0005-0 PCT.	1585	0060	3.79	0
000471341	ACT	LI2	0025-1 PCT.	1314	0045	3.42	0
000471341	ACT	LI3	0125-2 PCT.	1314	0065	4.95	0
000471341	ACT	LU1	0005-0 PCT.	0652	0046	7.06	0
000471341	ACT	LU2	0025-1 PCT.	1276	0056	4.39	0
000471341	ACT	LU3	0125-2 PCT.	0683	0061	8.93	0

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 710901 DETECTOR TA1537 SPECIES RHESUS/MONKEY DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	0352	0077	21.88	0
	A-C		SOLVENT	0641	0008	1.25	0
	ALI		TISSUE	0623	0031	4.98	0
	ALU		TISSUE	1229	0090	7.32	0
	ACP	LI	AMQ 333 UG/ML	1134	0428	37.74	0
	ACP	LU	AMQ 333 UG/ML	1158	0158	13.64	0
000471341	ACT	LI1	0005-0 PCT.	1251	0083	6.63	0
000471341	ACT	LI2	0025-1 PCT.	1078	0058	5.38	0
000471341	ACT	LI3	0125-2 PCT.	0906	0040	4.42	0
000471341	ACT	LU1	0005-0 PCT.	1750	0063	3.60	0
000471341	ACT	LU2	0025-1 PCT.	1715	0044	2.57	0
000471341	ACT	LU3	0125-2 PCT.	1376	0041	2.98	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 712503 DETECTOR TA1538 SPECIES RHESUS/MONKEY DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0700	0097	13.86	2
	A-C		SOLVENT	0689	0079	11.47	2
	ALI		TISSUE	0590	0073	12.37	2
	ALU		TISSUE	0802	0081	10.10	2
	ACP	LI	ANTH 67 UG/ML	0798	1229	154.01	2
	ACP	LU	ANTH 67 UG/ML	1046	0081	7.74	2
000471341	ACT	LI1	0005-0 PCT.	0682	0028	4.11	0
000471341	ACT	LI2	0025-1 PCT.	0890	0036	4.04	0
000471341	ACT	LI3	0125-2 PCT.	1089	0062	5.69	0
000471341	ACT	LU1	0005-0 PCT.	1132	0026	2.30	0
000471341	ACT	LU2	0025-1 PCT.	0914	0023	2.52	0
000471341	ACT	LU3	0125-2 PCT.	0985	0041	4.16	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102		PROJECT 2672					
EXPERIMENT 710403		DETECTOR TA98		SPECIES RHESUS/MONKEY		DATE - 07/22/77	
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	1852	0139	7.51	0
	A-C		SOLVENT	1660	0136	8.19	0
	ALI		TISSUE	0852	0124	14.55	0
	ALU		TISSUE	1167	0122	10.45	0
	ACP	LI	ANTH 67 UG/ML	1150	2319	201.65	0
	ACP	LU	ANTH 67 UG/ML	1789	0147	8.22	0
000471341	ACT	LI1	0005-0 PCT.	1710	0142	8.30	0
000471341	ACT	LI2	0025-1 PCT.	1695	0158	9.32	0
000471341	ACT	LI3	0125-2 PCT.	1484	0140	9.43	0
000471341	ACT	LU1	0005-0 PCT.	1089	0129	11.85	0
000471341	ACT	LU2	0025-1 PCT.	1221	0129	10.57	0
000471341	ACT	LU3	0125-2 PCT.	1419	0163	11.49	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 223-76-2102 PROJECT 2672
 EXPERIMENT 711302 DETECTOR 000004 SPECIES RHESUS/MONKEY DATE - 07/22/77

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	1110	0244	0121	21.98	10.90	0
	A-C		SOLVENT	1343	0108	0098	8.04	7.30	0
	ALI		TISSUE	1385	0225	0086	16.25	6.21	0
	ALU		TISSUE	1268	0263	0098	20.74	7.73	0
	ACP	LI	DMN 90 UM/ML	1370	0935	0743	68.25	54.23	0
	ACP	LU	DMN 90 UM/ML	1212	0248	0089	20.46	7.34	1
000471341	ACT	LI1	0005-0 PCT.	1048	0219	0128	20.90	12.21	0
000471341	ACT	LI2	0025-1 PCT.	1179	0176	0134	14.93	11.37	0
000471341	ACT	LI3	0125-2 PCT.	1066	0246	0135	23.08	12.66	0
000471341	ACT	LU1	0005-0 PCT.	1535	0224	0141	14.59	9.19	0
000471341	ACT	LU2	0025-1 PCT.	1155	0241	0129	20.87	11.17	0
000471341	ACT	LU3	0125-2 PCT.	1400	0239	0091	17.07	6.50	0